Yondelis Nueva Fase III . Istituto Nazionale del Tumori ( Milano ) Comunica el Inicio de la Fase III : Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23 (Mito23) .

ClinicalTrials Identifier: NCT02903004
Updated: 2016_09_15 .

Descriptive Information
Brief title	Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23 .
Official title	Randomized Phase III Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype patients_MITO-23 .
Brief summary
This is an open-label, prospective, multicenter, randomized Phase III, clinical trial evaluating the efficacy and safety of trabectedin in BRCA1 and BRCA2 mutation carrier and BRCAness phenotype advanced ovarian cancer patients in comparison to physician' choice chemotherapy. Arm A: Trabectedin 1.3 mg/mq d1 q 21 in 3 hours (central line) Arm B: Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/mq dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 Weekly Paclitaxel 80 mg/mq gg 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28 Patients will be randomly assigned in a 1:1 ratio to treatment arms. During the randomization process, patients will be stratified by •Platinum sensitivity •Measurable disease •Number of previous chemotherapy lines > vs < 3 •BRCA mutational status ... Administrative Data Organization name Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Organization study ID INT 181/15 Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Health Authority Italy: The Italian Medicines Agency .

China compra las dos mayores firmas de centros de oncología en España .

China Resources controlará los 17 hospitales de Imoncology y Oncosur .

ALBERTO VIGARIO / ARACELI MUÑOZ - 26/09/2016 .

Las dos principales compañías españolas con centros especializados de Oncología, la madrileña Imoncology y la andaluza Oncosur, tienen ya como máximo accionista al grupo estatal China Resources. Entre las dos empresas, que acaban de fusionarse, suman hasta 17 centros hospitalarios dedicados exclusivamente al tratamiento del cáncer.

El cambio a manos chinas de ambas empresas se ha producido en unos últimos cinco meses frenéticos de operaciones a nivel global, que han terminado por afectar a las firmas españolas, que aún así mantendrán sus respectivos equipos directivos.

...

Yondelis y Posibles Nuevas Combinaciones . VideoConferecia desde Instituto Mario Negri ( Italia , 26 Septiembre ) .

lunedì 26, 14:00-15:00

Alessandro e Noemi Guasti

Club delle 2: Sarah Uboldi

Dip. Oncologia

IRCCS Istituto di Ricerche Farmacologiche Mario Negri

Identification of effective new drug combinations with trabectedin

in videoconferenza da Milano